Yale awarded SPORE for head and neck cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Yale Cancer Center researchers were awarded a five-year, $11.7 million grant from NIH to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence.

The goal of the Yale Head and Neck Cancer SPORE is to address critical barriers to treatment of head and neck squamous cell carcinoma due to resistance to immunotherapy, DNA damaging, and targeted therapy.

The YHN-SPORE is a collaboration with Fox Chase Cancer Center and the University of North Carolina Lineberger Cancer Center, and is one of three SPOREs awarded to YCC.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login